Lite Strategy (LITS) Gross Margin (2016 - 2021)
Lite Strategy (LITS) posted Gross Margin of 100.0% for Q4 2021, little changed on a QoQ basis from 100.0% in Q3 2021, and up 392.0% year-over-year from 20.33% in Q4 2020.
Analysis
Lite Strategy (LITS) Gross Margin (2016 - 2021) Analysis & Trends
Lite Strategy has reported Gross Margin for 6 years, with the latest figure at 100.0% in Q4 2021.
- On a quarterly basis, Gross Margin rose 392.0% year-over-year to 100.0% in Q4 2021; TTM through Dec 2021 was 98.85%, a 395.0% increase from a year earlier, with the FY2022 full-year figure at 100.0%, up 405.0% from the prior year.
- Gross Margin was 100.0% for Q4 2021 at Lite Strategy, roughly flat from 100.0% in the prior quarter.
- The five-year high for Gross Margin was 100.0% in Q2 2021, with the low at 120.04% in Q2 2017.
- Average Gross Margin over 5 years is 13.13%, with a median of 38.47% recorded in 2019.
- The sharpest annual moves came in 2017 and 2018: Gross Margin slumped 19305 bps in 2017, then soared 15411 bps in 2018.
- Over 5 years, Gross Margin stood at 103.35% in 2017, then jumped by 149 bps to 50.76% in 2018, then retreated by 28 bps to 36.41% in 2019, then surged by 164 bps to 96.08% in 2020, then climbed by 4 bps to 100.0% in 2021.
- The last three Gross Margin figures came in at 100.0% (Q4 2021), 100.0% (Q3 2021), and 100.0% (Q2 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 72.04% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 79.76% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 85.33% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 91.59% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 90.43% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 35.86% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 76.90% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 71.60% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 80.31% |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 100.00% |
| Sep 30, 2021 | 100.00% |
| Jun 30, 2021 | 100.00% |
| Mar 31, 2021 | 95.01% |
| Dec 31, 2020 | 96.08% |
| Sep 30, 2020 | 92.33% |
| Jun 30, 2020 | 98.11% |
| Mar 31, 2020 | 30.87% |
| Dec 31, 2019 | 36.41% |
| Sep 30, 2019 | 40.54% |
| Jun 30, 2019 | 2.39% |
| Mar 31, 2019 | 6.89% |
| Dec 31, 2018 | 50.76% |
| Sep 30, 2018 | -102.66% |
| Jun 30, 2018 | -102.01% |
| Mar 31, 2018 | -114.78% |
| Dec 31, 2017 | -103.35% |
| Sep 30, 2017 | -118.37% |
| Jun 30, 2017 | -120.04% |
| Mar 31, 2017 | 74.54% |